Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
about
Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?Pharmacokinetic drug evaluation of dolutegravir plus rilpivirine for the treatment of HIV.Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.Pharmacokinetics, Antiviral Activity, and Safety of Rilpivirine in Pregnant Women with HIV-1 Infection: Results of a Phase 3b, Multicenter, Open-Label Study.
P2860
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
@en
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
@nl
type
label
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
@en
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
@nl
prefLabel
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
@en
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
@nl
P2093
P2860
P1476
Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
@en
P2093
Alice Stek
Anna H Tran
Brookie M Best
David E Shapiro
Edmund V Capparelli
IMPAACT P1026s Protocol Team
Jiajia Wang
Kathleen George
Kittipong Rungruengthanakit
Mark Mirochnick
P2860
P304
P356
10.1097/QAI.0000000000000968
P407
P577
2016-02-25T00:00:00Z